Regeneron Pharmaceuticals (REGN) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Regeneron Pharmaceuticals (REGN) has outperformed Zoetis (ZTS) over the past year, gaining 27.2% versus a loss of 49.9%. Over five years, REGN leads with a +34.1% price change compared with -64.6% for ZTS. Regeneron Pharmaceuticals is the larger company by market cap ($74.93 billion vs $29.93 billion), about 2.5 times the size, while Zoetis is growing revenue faster (+2.3% vs +1.0%).
On valuation, Zoetis trades at a lower forward P/E (11.1x vs 11.8x for Regeneron Pharmaceuticals). Zoetis offers the higher dividend yield (2.84% vs 0.50%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 28.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | ZTS |
|---|---|---|
| Share price | $727.79 | $72.43 |
| Market cap | $74.93B | $29.93B |
| 1-day change | -1.93% | +1.22% |
| YTD return | -3.85% | -43.13% |
| 1-year return | +27.24% | -49.88% |
| 5-year return | +34.14% | -64.62% |
| P/E ratio (TTM) | 18.00 | 11.91 |
| Forward P/E | 11.84 | 11.07 |
| EPS (TTM) | $40.44 | $6.08 |
| Dividend yield | 0.50% | 2.84% |
| Annual dividend | $3.64 | $2.06 |
| Revenue (latest FY) | $14.34B | $9.47B |
| Revenue growth (YoY) | +0.99% | +2.28% |
| Net income (latest FY) | $4.50B | $2.67B |
| Gross margin | — | 71.84% |
| Operating margin | 24.95% | — |
| Net margin | 31.41% | 28.23% |
| 52-week high | $859.34 | $148.30 |
| 52-week low | $541.00 | $68.77 |
| Distance from 52-week high | -15.31% | -51.16% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +17.65% | +32.55% |
| Average volume | 739.67K | 5.45M |
| Shares outstanding | 101.14M | 413.22M |
| Employees | 15,410 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regeneron Pharmaceuticals is about 2.5 times larger than Zoetis by market value ($74.93B vs $29.93B).
- REGN has outperformed ZTS by 77.1 percentage points over the past year.
- Regeneron Pharmaceuticals trades at a higher earnings multiple (18.0x vs 11.9x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.84% vs 0.50%).
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
REGN vs ZTS FAQ
Which is bigger, Regeneron Pharmaceuticals or Zoetis?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $74.93B compared with $29.93B for Zoetis (ZTS).
Which stock has performed better over the past year, REGN or ZTS?
REGN returned +27.24% over the past 12 months, compared with -49.88% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, REGN or ZTS?
ZTS has the lower trailing P/E at 11.9, versus 18.0 for REGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Regeneron Pharmaceuticals or Zoetis?
Zoetis has the higher yield at 2.84%, compared with 0.50% for Regeneron Pharmaceuticals.
Are Regeneron Pharmaceuticals and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.